Your browser doesn't support javascript.
Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19.
Cabezón Villalba, Gonzalo; Amat-Santos, Ignacio J; Dueñas, Carlos; Lopez Otero, Diego; Catala, Pablo; Aparisi, Alvaro; López-Pais, Javier; Cacho Antonio, Carla Eugenia; Candela, Jordi; Antúnez Muiños, Pablo; Gil, Jose Francisco; Gonzalez Ferrero, Teba; Marcos, Marta; Pérez-Poza, Marta; Rojas, Gino; Otero Garcia, Oscar; Veras, Carlos; Jiménez Ramos, Victor; Uribarri, Aitor; Revilla, Ana; Garcia-Granja, Pablo Elpidio; Gómez, Itziar; González-Juanatey, José Ramón; San Román, J Alberto.
  • Cabezón Villalba G; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Amat-Santos IJ; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Dueñas C; Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Lopez Otero D; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Catala P; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Aparisi A; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • López-Pais J; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Cacho Antonio CE; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Candela J; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Antúnez Muiños P; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Gil JF; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Gonzalez Ferrero T; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Marcos M; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Pérez-Poza M; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Rojas G; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Otero Garcia O; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Veras C; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Jiménez Ramos V; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • Uribarri A; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Revilla A; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Garcia-Granja PE; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • Gómez I; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain.
  • González-Juanatey JR; Complejo Hospitalario Universitario de Santiago de Compostela, Rua da Choupana s/n, 15702 Santiago de Compostela, Spain.
  • San Román JA; Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clínico Universitario, Valladolid, Spain. asanroman@secardiologia.es.
Cardiol J ; 28(3): 360-368, 2021.
Article in English | MEDLINE | ID: covidwho-1178544
ABSTRACT

BACKGROUND:

Cardiovascular risk factors and usage of cardiovascular medication are prevalent among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular implications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease (HD) and taking cardiovascular medications in a population diagnosed of COVID-19 who required hospitalization. Also, we studied the development of cardiovascular events during hospitalization.

METHODS:

Consecutive patients with definitive diagnosis of COVID-19 made by a positive real time- -polymerase chain reaction of nasopharyngeal swabs who were admitted to the hospital from March 15 to April 14 were included in a retrospective registry. The association of HD with mortality and with mortality or respiratory failure were the primary and secondary objectives, respectively.

RESULTS:

A total of 859 patients were included in the present analysis. Cardiovascular risk factors were related to death, particularly diabetes mellitus (hazard ratio in the multivariate

analysis:

1.810 [1.159- -2.827], p = 0.009). A total of 113 (13.1%) patients had HD. The presence of HD identified a group of patients with higher mortality (35.4% vs. 18.2%, p < 0.001) but HD was not independently related to prognosis; renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, diuretics and beta-blockers did not worsen prognosis. Statins were independently associated with decreased mortality (0.551 [0.329-0.921], p = 0.023). Cardiovascular events during hospitalization identified a group of patients with poor outcome (mortality 31.8% vs. 19.3% without cardiovascular events, p = 0.007).

CONCLUSIONS:

The presence of HD is related to higher mortality. Cardiovascular medications taken before admission are not harmful, statins being protective. The development of cardiovascular events during the course of the disease is related to poor outcome.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Agents / Pandemics / COVID-19 / Heart Diseases Type of study: Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male Language: English Journal: Cardiol J Year: 2021 Document Type: Article Affiliation country: CJ.a2021.0034

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Agents / Pandemics / COVID-19 / Heart Diseases Type of study: Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male Language: English Journal: Cardiol J Year: 2021 Document Type: Article Affiliation country: CJ.a2021.0034